Catalog No.
PHE97401
Species reactivity
Human, Mouse, Rat
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Human PLK1 (Val415-Ser603).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
Serine/threonine-protein kinase 13,PLK-1,PLK1,PLK,STPK13,Serine/threonine-protein kinase PLK1,Polo-like kinase 1
Purification
Purified by antigen affinity column.
Accession
P53350
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
4D label-free quantitative proteomic and phosphoproteomic profiling of the kidney in rat models of antimyeloperoxidase-associated vasculitis., PMID:40201969
Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial., PMID:39475591
Supramolecular Bioconjugation Strategy for Antibody-Targeted Delivery of siRNA., PMID:39321037
PLK1-activating IFI16-STING-TBK1 pathway induces apoptosis of intestinal epithelial cells in patients with intestinal Behçet's syndrome., PMID:38676954
An Antibody-CRISPR/Cas Conjugate Platform for Target-Specific Delivery and Gene Editing in Cancer., PMID:38552157
O-GlcNAcylation stimulates the deubiquitination activity of USP16 and regulates cell cycle progression., PMID:38462164
Multidimensional screening of pancreatic cancer spheroids reveals vulnerabilities in mitotic and cell-matrix adhesion signaling that associate with metastatic progression and decreased patient survival., PMID:38382357
Targeted delivery of immune-stimulating bispecific RNA, inducing apoptosis and anti-tumor immunity in cancer cells., PMID:38380254
PLK1 phosphorylates RhoGDI1 and promotes cancer cell migration and invasion., PMID:38355643
Targeted delivery of polo-like kinase 1 siRNA nanoparticles using an EGFR-PEG bispecific antibody inhibits proliferation of high-risk neuroblastoma., PMID:38341177
Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study., PMID:38231047
Genetic and immune microenvironment characterization of HER2-positive gastric cancer: Their association with response to trastuzumab-based treatment., PMID:36916290
Regulated Induced Proximity Targeting Chimeras (RIPTACs): a Novel Heterobifunctional Small Molecule Therapeutic Strategy for Killing Cancer Cells Selectively., PMID:36711980
HER-2-mediated nano-delivery of molecular targeted drug potently suppresses orthotopic epithelial ovarian cancer and metastasis., PMID:35995316
Multiomics characterization implicates PTK7 in ovarian cancer EMT and cell plasticity and offers strategies for therapeutic intervention., PMID:35977930
Antibody for Serine 65 Phosphorylated Ubiquitin Identifies PLK1-Mediated Phosphorylation of Mitotic Proteins and APC1., PMID:35956818
Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment., PMID:35871223
Identification of polo-like kinase 1 as a therapeutic target in murine lupus., PMID:35024139
Conserved Mitotic Phosphorylation of a Proteasome Subunit Regulates Cell Proliferation., PMID:34831298
Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies., PMID:34625423
Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer., PMID:33990570
In search for biomarkers and potential drug targets for uterine serous endometrial cancer., PMID:33754208
STK39 is a novel kinase contributing to the progression of hepatocellular carcinoma by the PLK1/ERK signaling pathway., PMID:33500714
Emerging drugs for the treatment of chronic myelomonocytic leukemia., PMID:33280448
CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy., PMID:33208369
Polo-like Kinase 1 as an emerging drug target: structure, function and therapeutic implications., PMID:32886539
Developing an Arrayed CRISPR-Cas9 Co-Culture Screen for Immuno-Oncology Target ID., PMID:32375580
PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer., PMID:31563561
Albatross/FBF1 contributes to both centriole duplication and centrosome separation., PMID:30318703
7-O-Methylwogonin from Scutellaria baicalensis Disturbs Mitotic Progression by Inhibiting Plk1 Activity in Hep3B Cells., PMID:30199903
Immunohistochemical expression of polo-like kinase 1 in oral squamous cell carcinoma and oral submucous fibrosis., PMID:29652009
Systemic Administration of siRNA with Anti-HB-EGF Antibody-Modified Lipid Nanoparticles for the Treatment of Triple-Negative Breast Cancer., PMID:29502423
Progesterone Receptor Membrane Component 1 suppresses the p53 and Wnt/β-catenin pathways to promote human pluripotent stem cell self-renewal., PMID:29445107
Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer., PMID:29391599
The responses of cancer cells to PLK1 inhibitors reveal a novel protective role for p53 in maintaining centrosome separation., PMID:29170437
The screening and analysis of protein signatures and signaling associated with chemoresistance based on Protein Pathway Array technology in gastric cancer., PMID:29115543
Inhibition of Suicidal Erythrocyte Death by Volasertib., PMID:29035889
A novel immunofluorescence method to visualize microtubules in the antiparallel overlaps of microtubule-plus ends in the anaphase and telophase midzone., PMID:28942021
Plk1 regulates contraction of postmitotic smooth muscle cells and is required for vascular homeostasis., PMID:28692064
Nutriproteomic Analysis of Hwangmaemok-Induced Antiangiogenic Effect Using Antibody-Arrayed Protein Chip Assay., PMID:28581882
A Brief Report of Immunohistochemical Markers to Identify Aggressive Hepatoblastoma., PMID:28187036
Targeted Treatment of Metastatic Breast Cancer by PLK1 siRNA Delivered by an Antioxidant Nanoparticle Platform., PMID:28138033
Expression of genes encoding centrosomal proteins and the humoral response against these proteins in chronic myeloid leukemia., PMID:27840977
Geldanamycin, an inhibitor of Hsp90, increases paclitaxel-mediated toxicity in ovarian cancer cells through sustained activation of the p38/H2AX axis., PMID:27629142
Novel antibodies to phosphorylated α-synuclein serine 129 and NFL serine 473 demonstrate the close molecular homology of these epitopes., PMID:27503460
Integrin signaling via FAK-Src controls cytokinetic abscission by decelerating PLK1 degradation and subsequent recruitment of CEP55 at the midbody., PMID:27127172
Sialic Acid-Targeted Nanovectors with Phenylboronic Acid-Grafted Polyethylenimine Robustly Enhance siRNA-Based Cancer Therapy., PMID:27007621
The Bub1-Plk1 kinase complex promotes spindle checkpoint signalling through Cdc20 phosphorylation., PMID:26912231
Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells., PMID:26573800
Activation of the endomitotic spindle assembly checkpoint and thrombocytopenia in Plk1-deficient mice., PMID:26185128
For research use only. Not for human or drug use.
